Halozyme Therapeutics (HALO) News
NASDAQ: HALOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
110.42+0.58 (+0.53%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
HALO news summary
We found 12 recent headlines mentioning Halozyme Therapeutics (HALO): 5 in the past week and 9 in the past 30 days, most often from Nasdaq. For price context, HALO is up 0.53% at $110.42. The most recent story, "Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data", was published by Nasdaq on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Halozyme Therapeutics headlines
- Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data(RTTNews) - This week, biopharmaceutical companies saw a busy week of regulatory decisions, strategic partnerships and clinical developments, alongside pipeline setbacks and workforce reductions.NasdaqABBV, ALVO, ARGX, BBIO
- HALO Wins Court Order Blocking Merck's Keytruda SC in EuropeHalozyme wins a Dutch court order blocking Merck's Keytruda SC in eight European markets, strengthening its position in the patent dispute.NasdaqHALO, JNJ, MRK, ARGX
- Halozyme Wins Dutch Patent Case Against Merck Over Keytruda SC(RTTNews) - Halozyme Therapeutics, Inc. (HALO) announced that the specialised Dutch patent court of The Hague found that Merck & Co., Inc. (MRK) infringed Halozyme's EP622 patent through its…NasdaqHALO, MRK, ET
- HALO Expands ENHANZE Collaboration & Licensing Deal With ARGXHalozyme expands its ENHANZE pact with argenx to eight targets, opening the door to new milestones and royalties as revenue growth accelerates.NasdaqHALO, JNJ, ARGX, HOWL
- Halozyme, Argenx Expand ENHANZE Collaboration With Two Additional Targets(RTTNews) - Halozyme Therapeutics, Inc. (HALO) announced an expansion of its global collaboration with argenx SE(ARGX), granting the company exclusive access to its ENHANZE drug-delivery technology…NasdaqARGX, HALO
- Why Women-Run Companies Deserve a Place in Your PortfolioBMY, HALO, TGT, NEO and ROST stocks show how women-led companies are redefining growth with discipline, agility and results.NasdaqBMY, TGT, ROST, HALO
- Notable ETF Outflow Detected - XBI, TWST, HALO, NTRALooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR S&P Biotech ETF (Symbol: XBI) where we have…NasdaqXBI, TWST, HALO, NTRA
- Biotech ETFs to Buy as Cancer Drug Breakthroughs AccelerateBiotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.NasdaqAMGN, ILMN, MRNA, HALO
- State Street SPDR S&P Biotech ETF Experiences Big OutflowLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the State Street SPDR S&P Biotech ETF (Symbol: XBI) where we have…NasdaqXBI, TWST, HALO, NTRA
- Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?Key PointsArgenx's top and bottom lines are growing robustly.NasdaqARGX, SPGI, HALO
- HALO Stock Rises 36% in a Month: Here's What You Should KnowHalozyme stock jumps 36% in a month as strong ENHANZE-driven royalties and recently raised 2026 guidance boost investor confidence.NasdaqHALO, JNJ, RGEN, ARGX
- Noteworthy ETF Outflows: FBT, ONC, HALO, NEOLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the First Trust NYSE Arca Biotechnology Index Fund (Symbol: FBT) where we…NasdaqFBT, ONC, HALO, NEO